Linnaeus Therapeutics LLC
Promoting resilience against cancer, cardiometabolic disease, and aging
Philadelphia, United States · Founded 2018 · $1000K raised
- Headquarters
- Philadelphia, Pennsylvania
- Employees
- 1–10
- Founded
- 2018
- Business Model
- B2G
- Website
- linnaeustx.com
- Total Funding
- $1000K
- Last Round
- Seed
- Rounds
- 3
About
Linnaeus Therapeutics is a clinical-stage biopharmaceutical company developing GPER-targeted medicines for cancer, cardiometabolic disease, and healthy aging. Their lead candidate, LNS8801, is a first-in-class oral GPER agonist with clinical evidence of antitumor activity and cardiometabolic benefits. The company has received multiple NCI SBIR awards totaling over $8M and is collaborating with Merck on combination trials with KEYTRUDA.
Summary
Linnaeus Therapeutics LLC is a Biotech company based in Philadelphia, United States, founded in 2018. It has raised $1000K in total across 3 rounds. Investors include Kairos Ventures and ARPA-H.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Unknown
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...